Redx Pharma to be Acquired by Skye Bioscience
Cooley advised Redx Pharma, a U.K. based, privately-held clinical-stage biotechnology company focused on developing novel, small molecule, targeted medicines for fibrotic disease, on its agreement to be acquired by Skye Bioscience, a clinical-stage biotechnology company. In connection with the transaction, Cooley also advised Redx Pharma on concurrent aggregate financings of […]
Actio Biosciences to be Acquired by Jazz Pharmaceuticals for Up to $1.32 Billion
Cooley advised Actio Biosciences, a clinical-stage biotechnology company advancing the translation of genetic insights into novel small molecule precision medicines, on its agreement to be acquired by Jazz Pharmaceuticals for $820 million upfront payment and up to $500 million in potential approval and sales milestones. Actio Biosciences to Be Acquired […]
Professional Fighters League Merger With Most Valuable Promotions
Cooley advised the Professional Fighters League (PFL), a global mixed martial arts organization and one of the world’s leading combat sports properties, on a landmark merger with Most Valuable Promotions (MVP), a combat sports company co-founded by Jake Paul and Nakisa Bidarian. Cooley Advises Professional Fighters League on Merger With […]
Procore Technologies to Acquire DroneDeploy for Approximately $845 Million
Cooley advised Procore Technologies, the leading global provider of construction management software, on its agreement to acquire DroneDeploy, the robotics and visual intelligence platform for the built world that is used on over 3 million jobsites across more than 180 countries. Procore Technologies to Acquire DroneDeploy for Approximately $845 Million
Canoe Intelligence to be Acquired by Bloomberg
Cooley advised Canoe Intelligence, a leading AI-powered data management and intelligence platform for automating private markets data collection and delivery, on its agreement to be acquired by Bloomberg, a global leader in business and financial information. Canoe Intelligence to be Acquired by Bloomberg
Vidya Therapeutics Sale to Processa Pharmaceuticals
Cooley advised Vidya Therapeutics, a clinical-stage biotechnology company developing VT-7208, a Bruton’s tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases with an initial focus on potentially best-in-class BTK inhibition in food allergy, chronic spontaneous urticaria and relapsing multiple sclerosis, on its sale to Processa Pharmaceuticals, a clinical-stage pharmaceutical company. Vidya Therapeutics […]
Research Alliance Corporation III to Combine with Oak Hill Bio
Cooley advised Research Alliance Corporation III (RACC), a special purpose acquisition company (SPAC) sponsored by RA Capital Management, on its definitive business combination agreement with Oak Hill Bio to create a publicly listed rare disease biotechnology company to advance antisense oligonucleotide therapy rugonersen for Angelman syndrome. Research Alliance Corporation III […]
Copra Acquired by The Vita Coco Company
Cooley advised Copra, one of the leading producers of super-premium Thai Nam Hom coconut water, on its acquisition by The Vita Coco Company, a leading high-growth platform of better-for-you beverage brands. Copra Acquired by The Vita Coco Company
Scancell to Acquire Neuphoria
Cooley advised Scancell, a late-stage clinical biotechnology company, on its agreement to acquire Neuphoria Therapeutics, a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. In connection with the transaction, Cooley also advised Scancell on a concurrent private financing of $89 […]
Keyrock Acquires BlockFills’ Trading and Brokerage Assets
Cooley advised Keyrock, a global crypto investment group, on the completion of its acquisition of assets of BlockFills’ institutional digital asset trading and brokerage business. Keyrock Acquires BlockFills’ Trading and Brokerage Assets